Skip to Main Content

Paper Details

Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression.
J Clin Invest
7
2023
-specific CD8+ T cells, CD4, CD4+, CD4+ and CD8+ T cells, CD4+/CD8+ T cell, CD8, CD8+, NeoAg, NeoAg-specific CD8+ T cells, PD-L1, PD-L1+ tumor-initiating cancer stem cells, T cells, autologous, cancer, cancers, neoantigen, squamous cell tumor, tCSC, tumor, tumors
Author NameAffiliation
Jason A GreenbaumLa Jolla Institute for Immunology
Ezra E W CohenUniversity of California San Diego Moores Cancer Center
Bjoern PetersLa Jolla Institute for Immunology
Bjoern PetersUniversity of California San Diego
Bjoern PetersLa Jolla Institute for Immunology
Bjoern PetersUniversity of California San Diego
  • 1 - 6

Datasets

Release 1.2